<DOC>
	<DOCNO>NCT02460354</DOCNO>
	<brief_summary>The purpose study determine whether metformin increase urine concentration ( osmolality ) decrease amount urine patient congenital nephrogenic diabetes insipidus ( NDI ) .</brief_summary>
	<brief_title>Metformin Congenital Nephrogenic Diabetes Insipidus</brief_title>
	<detailed_description>Nephrogenic diabetes insipidus ( NDI ) genetic disease . Patients disease make large amount urine kidneys n't hold water . The large amount urine mean patient need urinate frequently . They also increase risk dehydration n't drink enough . The large amount urine sometimes damage bladder kidney . There medicine may help patient urinate less , effective . There evidence animal study medication call metformin may help patient NDI urinate less .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Insipidus</mesh_term>
	<mesh_term>Diabetes Insipidus , Nephrogenic</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Arginine Vasopressin</mesh_term>
	<criteria>Males document mutation vasopressin type 2 receptor ( V2R ) Willing provide consent and/or assent appropriate Capable provide urine sample dictate protocol Urinary incontinence Subjects heart disease , liver disease , diabetes , cancer , significant disease Nephrogenic Diabetes Insipidus ( NDI ) Subjects significant renal dysfunction ( define calculate glomerular filtration rate ( GFR ) &lt; 80 ml/min/1.73 m^2 ) Subjects acquire NDI</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Congenital nephrogenic diabetes insipidus</keyword>
</DOC>